CYTOSORBENTS CORPORATION
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|
| Revenue | $15.2M | $9.5M | $4.8M | $4.1M | $2.4M | $1.3M | $36.1K |
| Cost of Revenue | $5.5M | $4.0M | $2.2M | $2.1M | $1.9M | $319.3K | $11.8K |
| Gross Profit | $9.6M | $5.6M | $2.6M | $2.0M | $511.1K | $1.0M | $24.3K |
| Gross Margin | 63.6% | 58.5% | 53.8% | 48.2% | 21.1% | 76.2% | 67.4% |
| Operating Expenses | |||||||
| Research & Development | $3.2M | $4.1M | $3.9M | $2.4M | $1.7M | $2.5M | $2.9M |
| SG&A Expense | $14.9M | $11.8M | $6.9M | $5.6M | $2.6M | $1.4M | $1.2M |
| Operating Income | $-9.8M | $-11.5M | $-9.3M | $-6.9M | $-4.7M | $-3.5M | $-4.4M |
| Operating Margin | -65.0% | -120.6% | -194.2% | -167.2% | -194.5% | -259.9% | -12,297.7% |
| Interest Expense | — | — | $0 | $199.0K | $311.0K | $235.8K | $516.3K |
| Pretax Income | $-9.1M | $-12.1M | $-9.8M | $-9.7M | $-5.1M | $-4.1M | $-5.5M |
| Income Tax Expense | $-676.7K | $-318.6K | $-324.6K | $-385.6K | $-458.3K | $-391.8K | — |
| Net Income | $-8.5M | $-11.8M | $-9.5M | $-9.3M | $-4.7M | $-3.7M | $-5.5M |
| Net Margin | -55.8% | -123.5% | -197.8% | -226.1% | -193.1% | -272.8% | -15,193.9% |
| EPS (Basic) | $-0.32 | $-0.46 | $-0.38 | $-1.29 | $-0.75 | $-0.03 | $-0.05 |
| EPS (Diluted) | $-0.32 | $-0.46 | $-0.38 | $-1.29 | $-0.75 | $-0.03 | $-0.05 |
| Shares Outstanding (Basic) | 29.0M | 25.5M | 25.4M | 23.3M | 10.1M | 215.0M | 177.6M |
| Shares Outstanding (Diluted) | 29.0M | 25.5M | 25.4M | 23.3M | 10.1M | 215.0M | 177.6M |
| Dividends Per Share | — | — | — | — | — | — | — |